In this issue of Blood, Dimopoulos and colleagues report on a prospective multicenter clinical trial conducted by the European Myeloma Network (EMN) that evaluated the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with untreated, symptomatic Waldenström macroglobulinemia (WM). 1 U sing a novel schedule of administration, patients were transitioned from twice weekly to weekly administration of bortezomib after cycle 1. An overall response rate (ORR) of 85% was attained, including very good partial response (VGPR) or better responses in 10% of patients. The median progression-free survival (PFS) in this study was 43 months, and patents with VGPR or better had longer PFS. No maintenance therapy was used. Treatment-related peripheral neuropathy (PN) occurred in 46% of patients, with grade 3 events representing 7%; 8% of patients discontinued proteasome inhibitor therapy for PN. Rituximab was also omitted during cycle 1 to prevent immunoglobulin M (IgM) flaring, a common and potentially lifethreatening complication in WM patients with high serum IgM levels. Following cycle 1 of administration of bortezomib alone, rituximab and dexamethasone were added, and subsequent IgM flaring was observed in 11% of patients without need for preemptive plasmapheresis.
The study by the EMN group addresses some important hurdles that impact delivery of safe and effective therapy for WM patients. Bortezomib is a highly active and stem cell-sparing therapy, particularly in combination with rituximab and/or steroids in WM. 
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In summary, the study by the EMN provides a practical approach for dealing with the perils associated with proteasome inhibitor and rituximab-based therapy in WM patients. PN, however, continues to remain a significant problem with bortezomib use despite schedule modifications in WM patients. More work is still needed to optimize proteasome inhibitor-based therapy in WM patients.
Conflict-of-interest disclosure: S.P.T. has received research support and speaking honoraria, and was a consultant for, Takeda/Millenium Pharmaceuticals, Inc and Onyx Pharmaceuticals, Inc. AIDS-lymphoma (ARL): one more step along the way   ---------------------------------------------------------------------------------------------------- In this issue of Blood, some of the controversies surrounding optimal therapy for patients with AIDS-related lymphoma (ARL) are now clarified by the analyses of Barta et al. 1 T he profound immunodeficiency characteristic of HIV infection serves as an etiologic factor in the pathogenesis of ARL while also limiting the efficacy of standard multiagent chemotherapy due to development of intercurrent life-threatening infections, as well as depletion in bone marrow reserves. Prior to the availability of combination antiretroviral therapy (cART), use of standard multiagent chemotherapy was extremely difficult due to these factors, and low-dose chemotherapy was advocated. 
